Core Points - China submitted its approval of the "Agreement on the Conservation and Sustainable Use of Marine Biological Diversity of Areas Beyond National Jurisdiction" to the UN Secretary-General, marking a significant step in global marine governance and China's commitment to multilateralism [1][3] - The agreement, which will come into effect on January 17, 2026, is a result of 19 years of negotiations among over 190 UN member states and is seen as a major achievement in multilateral negotiations [3][11] Group 1: Global Governance and Sustainable Development - The agreement focuses on the conservation and sustainable use of marine biodiversity in areas beyond national jurisdiction, establishing key frameworks such as deep-sea genetic resources management and environmental impact assessments [3][4] - China's participation in the agreement reflects its commitment to ecological civilization and global governance, aiming to contribute to sustainable development goals [3][5] Group 2: National Interests and Global Responsibilities - As a leading marine nation, China's decision to approve the agreement is driven by its development needs and a sense of global responsibility [5] - The approval includes four declarations to protect China's interests, ensuring that pre-agreement deep-sea genetic resources are not subject to the agreement's constraints [5][6] Group 3: Institutional Adjustments and Industry Transformation - Following the agreement's enactment, China will undergo institutional adjustments and industry transformations, with the Ministry of Natural Resources taking the lead in compliance efforts [7][8] - The agreement is expected to promote a shift towards greener and smarter industries, enhancing resource utilization and developing high-value products through international collaboration [8] Group 4: International Cooperation and Capacity Building - China is actively promoting international cooperation under the agreement, having signed marine cooperation agreements with over 50 countries and organizations [10] - Initiatives such as the establishment of international research centers and joint marine research projects aim to enhance scientific understanding and collaboration in deep-sea exploration [10]

12月24日，兽用肿瘤治疗公司Jenga Biosciences, Inc. （Jenga Biosciences）宣布其已与专注于动物保健医 药的生物技术公司——北京伟杰信生物科技有限公司（伟杰信生物）签署了一项独家许可协议。 根据协议，Jenga Biosciences将获得一款免疫检查点抑制剂，即犬特异性抗PD-1单克隆抗体的开发和商 业化权益。 根据协议条款，Jenga Biosciences将获得该疗法在中国以外所有国家的独家开发、生产和商业化权利。 该协议约定，未来根据达成开发、注册和商业里程碑的情况，Jenga Biosciences潜在将向伟杰信生物支 付总额高达1亿美元的款项。 ...

Group 1 - The successful inclusion of Baiaosaitu in the Hong Kong Stock Connect marks a significant milestone in the company's capital market development, indicating a new stage in capital accessibility, market recognition, and long-term investment value [1][3] - Baiaosaitu is an international biotechnology company driven by innovative technology for new drug development, focusing on "high-quality source molecule acquisition" and "high-certainty in vivo validation" as its core processes, supported by a leading global platform of "full human antibody library + target humanized mouse library" [2] - The inclusion of H-shares in the Hong Kong Stock Connect allows eligible domestic institutional and individual investors to directly invest in Baiaosaitu's H-shares through the Shanghai and Shenzhen Stock Exchanges [3] Group 2 - The H-share inclusion in the Hong Kong Stock Connect represents a systemic breakthrough in the capital market and will create a more efficient synergy with the company's A-share Sci-Tech Innovation Board platform, further supporting the company's ongoing investments in technology platform transformation, global business expansion, and long-term strategic implementation [5] - Baiaosaitu aims to maintain a technology innovation-oriented approach, deepen its global cooperation network, and steadily enhance operational quality and communication with the capital market, while committing to a more open, transparent, and stable posture to reward long-term investors [5] - The company is positioned as a "global source of new drugs," contributing long-term value to the high-quality development of China's biopharmaceutical industry and global innovation [5]

Group 1 - Sanofi announced a $2.2 billion acquisition of Dynavax at $15.50 per share, a 39% premium over its last closing price, adding a hepatitis B vaccine and an experimental shingles vaccine to its portfolio, with completion expected in Q1 2026 [2] - Apple's CEO Tim Cook purchased $2.95 million worth of Nike shares at an average price of $58.97, increasing his total holdings to 105,480 shares valued at approximately $6.04 million, contributing to a 2.3% rise in Nike's stock [2] - UiPath was added to the S&P MidCap 400 index, effective January 6, 2026, with RBC Capital raising its target price from $16 to $19, reflecting a stable business trend amid growing automation demand, resulting in a 6.6% stock increase [3] Group 2 - Toyota is recalling 55,405 vehicles in the U.S. due to potential issues with inverter bolts, leading to a 1.69% decline in its stock [2] - BP agreed to sell a 65% stake in its Castrol lubricants business to Stonepeak Partners for approximately $6 billion, indicating a strategic shift to raise cash for debt reduction and improve performance, with BP's stock rising 0.26% [3] - Goldman Sachs released a report highlighting disruptive opportunities in the aerospace sector, particularly focusing on the $3.5 billion contract for satellite construction and launch under the U.S. Department of Defense's PWSA project, with Rocket Lab securing its largest government order [4] Group 3 - Gold prices reached over $4,500 per ounce, silver surpassed $70 per ounce, and copper hit a record high of $12,159 per ton, marking significant increases in precious metals [4]

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. plans to sell part of its repurchased shares through centralized bidding, as the purpose of the share buyback has been achieved [2][3]. Group 1: Share Buyback Details - The company repurchased a total of 2,893,010 shares from February 8, 2024, to May 7, 2024, and has not sold or transferred any of these shares as of the announcement date [2]. - The shares will be sold within three years after the announcement of the buyback results, and any unsold shares will be canceled [2][7]. Group 2: Sale Plan - The company plans to sell up to 1,854,158 shares, which represents approximately 2% of the total share capital, within six months after the announcement [3][6]. - The sale will commence 15 trading days after the announcement, and the actual start date may be adjusted if the company's stock is suspended [6]. Group 3: Use of Proceeds - The funds from the sale will be used to supplement the company's working capital [9][11]. Group 4: Impact on Shareholding Structure - If the sale is completed, the number of shares in the repurchase account will decrease from 4,778,183 to 2,924,025, changing the holding percentage from 5.15% to 3.15% [10]. Group 5: Management's Statement - The management stated that the sale of repurchased shares will not have a significant impact on the company's operations, finances, or future development [11].

转自：成都日报锦观 工信部发布生物制造中试能力建设平台 金开微生物合成与生物制造中试研发平台是由金开生物牵头，以四川省食品发酵工业研究设计院为技术 支撑，联合省内多家科研院所、高校建设的中试研发平台。该平台建设有特色食品、生物基材料、菌种 培育、纯化制取、提取分离、活性特肥等6大特色中试车间，近三年已开展中试转化项目30余项。 中试是生物科技创新成果向工业生产转化的关键环节，是生物制造产业体系的重要支撑。记者了解到， 本次成都上榜的2个平台，以其特有的中试服务为产业发展提供硬核支撑。 成都雅途生物技术有限公司合成生物及发酵工程生物制造中试平台，在新药发现、高端药物及临床急需 重大品种开发以及关键制备工艺开发等领域具备先发优势。该平台在行业内率先倡导提出中试服务"交 钥匙工程"，提供一体化解决方案，覆盖从菌种构建、工艺开发、质量研究到注册申报（药政）的全流 程服务。 成都2个平台首批上榜 本报讯 （成都日报锦观新闻记者 李艳玲） 近日，工业和信息化部办公厅发布生物制造中试能力建设平 台名单（第一批），成都2个平台上榜，分别是成都雅途生物技术有限公司合成生物及发酵工程生物制 造中试平台、成都金开生物工程有限公司金 ...

Core Viewpoint - The recent IPOs of two biotech companies, Huazhang Biotechnology and Hansai Aitai, faced significant declines on their debut trading days, indicating a bearish sentiment in the market for innovative drug companies, despite their initial hype and strong subscription rates [1][3][9]. Group 1: IPO Performance - Huazhang Biotechnology's stock fell nearly 30% on its first trading day, while Hansai Aitai's stock opened at 28.9 HKD, down 9.69% from its issue price of 32 HKD, and closed at 17.20 HKD, marking a 46.25% drop [1][3]. - Hansai Aitai's stock experienced a maximum intraday decline of 46.25%, failing to recover significantly by the end of the trading day [1][3]. Group 2: Subscription and Issuance Details - Hansai Aitai's global offering consisted of 18.32 million shares, with a public offering that was oversubscribed by 3074.09 times, resulting in a final allocation of 183.21 million shares, approximately 10% of the total offering [4][5]. - The final issue price was set at the upper limit of the range at 32 HKD, raising a net amount of 531 million HKD [5][6]. Group 3: Market Sentiment and Strategy - Both companies were initially viewed as "big meat" in the market due to their innovative drug offerings, yet their first-day performances fell short of expectations, reflecting a potential shift in investor sentiment towards unprofitable biotech firms [3][9]. - The adoption of the "Mechanism B" strategy, which favors institutional and cornerstone investors, did not yield the expected price stability for either company, as evidenced by their poor debut performances [9][10]. Group 4: Financial Performance and Valuation - Hansai Aitai reported losses of 85.16 million HKD, 117 million HKD, and 87.43 million HKD for the years 2023, 2024, and the first eight months of 2025, respectively [14]. - The company's post-IPO valuation reached 43.52 billion HKD, significantly higher than its pre-IPO valuation of approximately 16.15 billion HKD, raising concerns about its market valuation relative to industry averages [14].

Core Viewpoint - The recent IPOs of Huazhang Biotechnology and Hansai Aitai have faced significant market backlash, with both companies experiencing substantial stock price declines on their first trading days, indicating a potential shift in investor sentiment towards biotech firms, particularly those classified as "unprofitable 18A" [1][3][9]. Group 1: IPO Performance - Huazhang Biotechnology's stock fell nearly 30% on its debut, while Hansai Aitai's stock opened at 28.9 HKD, down 9.69% from its issue price of 32 HKD, and closed at 17.20 HKD, marking a 46.25% drop [1][3]. - Hansai Aitai's IPO was characterized by a high subscription rate of 3074.09 times for the public offering, with only 10% of shares allocated to this segment, reflecting strong initial interest despite the subsequent price drop [3][4]. Group 2: Company Background and Strategy - Hansai Aitai is a biotech company focused on innovative therapies for cancer and autoimmune diseases, utilizing its proprietary VersatiBody platform to develop dual-function or multi-functional molecules [10]. - The company has a rich pipeline, including its lead product HX009, a PD-1/SIRPα dual-function antibody fusion protein, which is currently in various clinical trials [11]. Group 3: Financial Metrics and Valuation - The IPO pricing was set at the upper limit of 32 HKD, raising approximately 5.31 billion HKD, but the post-IPO market valuation of 23.43 billion HKD corresponds to a high price-to-book ratio of 21.77, significantly above the industry average of 4.81 [4][13]. - Financial losses for Hansai Aitai were reported at 85.16 million HKD, 117 million HKD, and 87.43 million HKD for the years 2023, 2024, and the first eight months of 2025, respectively, raising concerns about its valuation amidst ongoing losses [12].

Group 1 - Goldman Sachs reported that hedge funds sold more U.S. healthcare stocks than they bought last week, marking the first time in 14 weeks this has occurred due to impending subsidy expirations [1] - Approximately 24 million Americans purchased health insurance through the Affordable Care Act, with increased costs expected if Congress does not act before the subsidies expire on December 31 [1] - The ratio of short positions to long positions exceeded eight to one, indicating a bearish sentiment in the healthcare sector [1] Group 2 - The House Republicans passed a bill supported by Trump aimed at reducing premiums for some groups while cutting subsidies and increasing costs for others starting January 2027 [2] - Hims & Hers Health and Bruker were identified as the most favored short targets among mid-cap stocks in the U.S. according to Hazeltree data [2]

Core Viewpoint - Abivax S.A. has seen significant stock price increases, with a recent rise attributed to rumors of a potential acquisition by Eli Lilly, which is in preliminary discussions with French authorities [1] Stock Performance - Abivax S.A. stock rose by 1.01% in pre-market trading, reaching $140.12 - The stock hit an intraday high of $139.62, marking a historical peak - The closing price was $138.72, reflecting a 20.69% increase for the day - Year-to-date, the stock has surged by 1795% [1]